Stock Rating Upgrade
Of late the Value Trend Rating for Acadia Pharmaceuticals Inc (NASDAQ: ACAD) rose significantly from F to C reflecting improving fundamentals and high Appreciation Potential.
Recent Price Action
On 3/14/25, Acadia Pharmaceuticals Inc (NASDAQ: ACAD) stock enjoyed a large increase of 4.3%, closing at $17.50. NORMAL trading volume accompanied the advance. The stock has been strong relative to the market over the last nine months but has declined -0.6% during the last week.
Current PriceTarget Research Rating
Acadia Pharmaceuticals has a current Value Trend Rating of C (Low Neutral). This VT Rating rose significantly in recent days from F previously. The Value Trend Rating reflects consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Acadia Pharmaceuticals has a slightly negative Appreciation Score of 35 and a neutral Power Rating of 52, resulting in the Low Neutral Value Trend Rating.
Be the first to comment